ANAEMIA ASSOCIATED WITH CHR. RENAL FAILURE IN PATIENTS ON HAEMODIALYSIS, BY IV INJ. OVER 1-5 MINUTES OR BY S/C INJ. (MAX. 1 ML PER INJ. SITE), INITIALLY 50 UNITS/KG 3 TIMES WEEKLY ADJUSTED ACCORDING TO RESPONSE IN STEPS OF 25 UNITS/KG 3 TIMES WEEKLY AT INTERVALS OF AT LEAST 4 WEEKS.
MAINTENANCE DOSE (WHEN HAEMOGLOBIN CONCENTRATION OF 10-12 G/100 ML ACHIEVED), USUALLY A TOTAL OF 75-300 UNITS/KG WEEKLY (AS A SINGLE DOSE OR IN DIVIDED DOSES)
CHILD BY IV INJ. INITIALLY AS FOR ADULTS; MAINTENANCE DOSE (WHEN HAEMOGLOBIN CONCENTRATION OF 9.5-11 G/100 ML ACHIEVED), BODY-WEIGHT UNDER 10 KG USUALLY 75-150 UNITS/KG 3 TIMES WEEKLY, BODY-WEIGHT 10-30 KG USUALLY 60-150 UNITS/KG 3 TIMES WEEKLY, BODY-WEIGHT OVER 30 KG USUALLY 30-100 UNITS/KG 3 TIMES WEEKLY
NOTE: IV ROUTE PREFERRED
ANAEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE IN ADULTS ON PERITONEAL DIALYSIS, BY IV INJ. OVER 1-5 MINUTES OR BY S/C INJ. (MAX. 1 ML PER INJ. SITE), INITIALLY 50 UNITS/KG TWICE WEEKLY.
MAINTENANCE DOSE (WHEN HAEMOGLOBIN CONCENTRATION OF 10-12 G/100 ML ACHIEVED), 25-50 UNITS/KG TWICE WEEKLY
NOTE: IV ROUTE PREFERRED
SEVERE SYMPTOMATIC ANAEMIA OF RENAL ORIGIN IN ADULTS WITH RENAL INSUFFICIENCY NOT YET ON DIALYSIS, BY IV INJ. OVER 1-5 MINUTES OR BY S/C INJ. (MAX. 1 ML PER INJ SITE), INITIALLY 50 UNITS/KG 3 TIMES WEEKLY INCREASED ACCORDING TO RESPONSE IN STEPS OF 25 UNITS/KG 3 TIMES WEEKLY AT INTERVALS OF AT LEAST 4 WEEKS
MAINTENANCE DOSE (WHEN HAEMOGLOBIN CONCENTRATION OF 10-12 G/100 ML ACHIEVED), 17-33 UNITS/KG 3 TIMES WEEKLY; MAX. 200 UNITS/KG 3 TIMES WEEKLY
NOTE: IV ROUTE PREFERRED
ANAEMIA IN ADULTS RECEIVING CANCER CHEMOTHERAPY, BY S/C INJ (MAX. 1 ML PER INJ SITE), 150 UNITS/KG 3 TIMES WEEKLY (OR 450 UNITS/KG ONCE WEEKLY), INCREASED IF APPROPRIATE RISE IN HAEMOGLOBIN (OR RETICULOCYTE COUNT) NOT ACHIEVED AFTER 4 WEEKS TO 300 UNITS/KG 3 TIMES WEEKLY; DISCONTINUE IF INADEQUATE RESPONSE AFTER 4 WEEKS AT HIGHER DOSE; REDUCE DOSE BY 25-50% IF HAEMOGLOBIN RISE EXCEEDS 2 G/100 ML PER MONTH; SUSPEND IF HAEMOGLOBIN EXCEEDS 13 G/100 ML UNTIL IT FALLS TO 12 G/100 ML AND REINSTATE WITH DOSE AT 25% BELOW PREVIOUS DOSE; CONTINUE EPOETIN FOR 1 MONTH AFTER END OF CHEMOTHERAPY
TO INCREASE YIELD OF AUTOLOGOUS BLOOD (TO AVOID HOMOLOGOUS BLOOD) IN PREDONATION PROGRAMME IN MODERATE ANAEMIA EITHER WHEN LARGE VOLUME OF BLOOD REQUIRED OR WHEN SUFFICIENT BLOOD CANNOT BE SAVED FOR ELECTIVE MAJOR SURGERY, BY INTRAVENOUS INJECTION OVER 1-5 MINUTES, 600 UNITS/KG TWICE WEEKLY FOR 3 WEEKS BEFORE SURGERY; CONSULT PRODUCT LITERATURE FOR DETAILS AND ADVICE ON ENSURING HIGH IRON STORES
MODERATE ANAEMIA (HAEMOGLOBIN CONCENTRATION 10-13 G/100 ML) BEFORE ELECTIVE ORTHOPAEDIC SURGERY IN ADULTS WITH EXPECTED MODERATE BLOOD LOSS TO REDUCE EXPOSURE TO ALLOGENEIC TRANSFUSION OR IF AUTOLOGOUS TRANSFUSION UNAVAILABLE, BY SUBCUTANEOUS INJECTION (MAX. 1 ML PER INJECTION SITE), 600 UNITS/KG EVERY WEEK FOR 3 WEEKS BEFORE SURGERY AND ON DAY OF SURGERY OR 300 UNITS/KG DAILY FOR 15 DAYS STARTING 10 DAYS BEFORE SURGERY; CONSULT PRODUCT LITERATURE FOR DETAILS
ZIDOVUDINE-TREATED HIV-INFECTED - 100 UNITS/KG AS AN IV OR SC INJECTION TIW FOR 8 WEEKS.